Roche Holding AG / GlycArt Biotechnology AG

Chronic Lymphocytic Leukemia (CLL) / B-cell Non-Hodgkin Lymphoma

23K US cases/yr · 90.2% 5-year relative survival (CLL, 2016-2022)

Disease Overview

Chronic lymphocytic leukemia is the most common adult leukemia in Western countries, characterized by clonal expansion of mature CD20-positive B-cells. Median diagnosis age is 71; the disease is incurable outside of allogeneic transplant but generally indolent, with a 5-year relative survival of ~90%. CD20-directed antibodies have been a backbone of therapy since rituximab's late-1990s approval.

Competitive Landscape

At the time of the 2005 GlycArt deal, Genentech/Roche's Rituxan (rituximab) was the dominant CD20 antibody for B-cell malignancies, with Bayer/IDEC's Zevalin and Corixa/GSK's Bexxar as radio-immunoconjugate alternatives. The competitive question was who would build the next-generation CD20 follow-on: GlaxoSmithKline/Genmab's ofatumumab (Arzerra, type I, fully human) and Immunomedics' veltuzumab were already advancing. GlycArt's GlycoMAb glycoengineering platform produced afucosylated antibodies with markedly enhanced antibody-dependent cellular cytotoxicity (ADCC). The acquired lead, GA101, ultimately became obinutuzumab (Gazyva), approved by FDA in November 2013 for previously untreated CLL in combination with chlorambucil, then expanded to follicular lymphoma. The deal effectively gave Roche a defensible Rituxan successor for CLL/iNHL and locked in glycoengineering IP applicable across antibody franchises. For ~$182M, this is widely regarded as one of the highest-ROI Roche oncology bolt-ons of the decade.